{"id":433760,"date":"2026-05-09T18:53:09","date_gmt":"2026-05-09T18:53:09","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/433760\/"},"modified":"2026-05-09T18:53:09","modified_gmt":"2026-05-09T18:53:09","slug":"a-look-at-clover-health-clov-valuation-after-profitability-return-and-medicare-advantage-growth","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/433760\/","title":{"rendered":"A Look At Clover Health (CLOV) Valuation After Profitability Return And Medicare Advantage Growth"},"content":{"rendered":"\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/simplywall.st\/features\/portfolio?utm_medium=finance_user&amp;utm_campaign=updates_head_cta&amp;utm_source=yahoo&amp;blueprint=4567289\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Never miss an important update on your stock portfolio;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Never miss an important update on your stock portfolio&quot;}\" class=\"link \">Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.<\/p>\n<p>      Why Clover Health\u2019s latest earnings matter for shareholders    <\/p>\n<p class=\"yf-1fy9kyt\">Clover Health Investments (CLOV) sparked fresh attention after first quarter 2026 results showed a return to profitability, with US$27.3 million in net income and Medicare Advantage membership reaching about 156,000 members.<\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.simplywall.st\/company\/id\/b181a9f8-182e-48cc-b994-e8c063d4c75b?utm_medium=finance_user&amp;utm_campaign=cta_company_latest_analysis&amp;utm_source=yahoo\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:See our latest analysis for Clover Health Investments.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;See our latest analysis for Clover Health Investments.&quot;}\" class=\"link \">See our latest analysis for Clover Health Investments.<\/a><\/p>\n<p class=\"yf-1fy9kyt\">The strong first quarter has come alongside a sharp shift in sentiment, with a 48.4% 30 day share price return and a 32.4% 90 day share price return, contrasting with a 24.8% total shareholder return decline over the past year and a 196.8% total shareholder return over three years.<\/p>\n<p class=\"yf-1fy9kyt\">If Clover Health\u2019s use of technology in Medicare Advantage caught your eye, this is a good moment to look across healthcare related AI opportunities using our <a href=\"https:\/\/simplywall.st\/discover\/investing-ideas\/434426\/healthcare-ai\/us?utm_medium=finance_user&amp;utm_campaign=cta_screener_healthcare_ai&amp;utm_source=yahoo&amp;blueprint=4567289\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:35 healthcare AI stocks;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;35 healthcare AI stocks&quot;}\" class=\"link \">35 healthcare AI stocks<\/a><\/p>\n<p class=\"yf-1fy9kyt\">With the stock up 48.4% in a month and trading close to analyst targets, yet screening as materially below some intrinsic value estimates, investors now need to ask whether there is still a buying opportunity or whether the market is already pricing in future growth.<\/p>\n<p>      Most Popular Narrative: 10% Overvalued    <\/p>\n<p class=\"yf-1fy9kyt\">With Clover Health trading at $2.82 against a narrative fair value of $2.82, the widely followed model views the stock as slightly overvalued once the 10% premium to fair value is included.<\/p>\n<p class=\"yf-1kwbn3\">The analysts have a consensus price target of $2.82 for Clover Health Investments based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $3.2, and the most bearish reporting a price target of just $2.5.<\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.simplywall.st\/narratives\/cw2q5rwa-margin-pressures-and-healthcare-reforms-will-influence-future-medicare-advantage-dynamics?utm_medium=finance_user&amp;utm_campaign=cta_narrative_prompt_after_quote&amp;utm_source=yahoo\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Read the complete narrative.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Read the complete narrative.&quot;}\" class=\"link \">Read the complete narrative.<\/a><\/p>\n<p class=\"yf-1fy9kyt\">Want to see what is really driving that fair value figure? The narrative places significant weight on rapid earnings improvement and richer margins in its long-range forecasts.<\/p>\n<p class=\"yf-1fy9kyt\">Result: Fair Value of $2.82 (OVERVALUED)<\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.simplywall.st\/narratives\/cw2q5rwa-margin-pressures-and-healthcare-reforms-will-influence-future-medicare-advantage-dynamics?utm_medium=finance_user&amp;utm_campaign=cta_ai_narrative&amp;utm_source=yahoo\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Have a read of the narrative in full and understand what&#039;s behind the forecasts.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Have a read of the narrative in full and understand what&#039;s behind the forecasts.&quot;}\" class=\"link \">Have a read of the narrative in full and understand what&#8217;s behind the forecasts.<\/a><\/p>\n<p class=\"yf-1fy9kyt\">However, investors still need to watch rising medical and pharmacy utilization, as well as the risk that any Medicare Advantage reimbursement or policy changes could pressure margins and earnings.<\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.simplywall.st\/company\/id\/b181a9f8-182e-48cc-b994-e8c063d4c75b?utm_medium=finance_user&amp;utm_campaign=risks_narrative_cta&amp;utm_source=yahoo\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Find out about the key risks to this Clover Health Investments narrative.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Find out about the key risks to this Clover Health Investments narrative.&quot;}\" class=\"link \">Find out about the key risks to this Clover Health Investments narrative.<\/a><\/p>\n<p>      Another way to look at valuation     <\/p>\n<p class=\"yf-1fy9kyt\">Analysts see Clover Health as roughly 10% overvalued at $2.82 versus their $2.82 fair value, but the price based on sales tells a different story. The stock trades on a P\/S of 0.7x versus 1.2x for the US Healthcare industry and 1.9x for peers, while the fair ratio sits at 0.8x. That gap suggests the multiple could still move either up toward peers or down toward the fair ratio, so which outcome do you think is more realistic for this business?<\/p>\n<p class=\"yf-1fy9kyt\"><a href=\"https:\/\/www.simplywall.st\/company\/id\/b181a9f8-182e-48cc-b994-e8c063d4c75b\/valuation?utm_medium=finance_user&amp;utm_campaign=alternate_preferred_multiple_cta&amp;utm_source=yahoo\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:See what the numbers say about this price \u2014 find out in our valuation breakdown.;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;See what the numbers say about this price \u2014 find out in our valuation breakdown.&quot;}\" class=\"link \">See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a><\/p>\n<p>   <a href=\"https:\/\/www.simplywall.st\/\/company\/id\/b181a9f8-182e-48cc-b994-e8c063d4c75b\/valuation?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"NasdaqGS:CLOV P\/S Ratio as at May 2026\" loading=\"lazy\" height=\"380\" width=\"960\" class=\"yf-lglytj loader\"\/><\/a> NasdaqGS:CLOV P\/S Ratio as at May 2026        Next Steps   <\/p>\n<p class=\"yf-1fy9kyt\">With sentiment clearly mixed after such a sharp move in the share price, this is the time to look closely at the numbers, weigh both sides of the story and form your own view using our <a href=\"https:\/\/finance.yahoo.com\/quote\/CLOV\" data-ylk=\"slk:3 key rewards and 1 important warning sign;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;3 key rewards and 1 important warning sign&quot;}\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">3 key rewards and 1 important warning sign<\/a><\/p>\n<p>     Looking for more investment ideas?   <\/p>\n<p class=\"yf-1fy9kyt\">If you stop with just one stock, you could miss opportunities that better suit your goals, risk comfort and income needs across different parts of the market.<\/p>\n<p class=\"yf-1fy9kyt\"> This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n<p class=\"yf-1fy9kyt\">Companies discussed in this article include <a href=\"https:\/\/finance.yahoo.com\/quote\/CLOV\" data-ylk=\"slk:CLOV;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;CLOV&quot;}\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">CLOV<\/a>.<\/p>\n<p class=\"yf-1fy9kyt\">Have feedback on this article? Concerned about the content? <a href=\"https:\/\/investor-research.typeform.com\/to\/wvg6MFri#feedback_token=NDU2NzI4OToyZmFmOGYxNjAyYjI1ZWE2&amp;company=NasdaqGS:CLOV&amp;blueprintid=4567289\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Get in touch;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;Get in touch&quot;}\" class=\"link \">Get in touch<\/a> with us directly. Alternatively, email <a href=\"https:\/\/finance.yahoo.com\/markets\/stocks\/articles\/mailto:editorial-team@simplywallst.com?subject=Re%3A%20Your%20article%20on%20NasdaqGS%3ACLOV%20(yahoo)%20from%209th%20May%202026\" data-ylk=\"slk:editorial-team@simplywallst.com;elm:context_link;itc:0;sec:content-canvas\" data-yga=\"{&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yLinkText&quot;:&quot;editorial-team@simplywallst.com&quot;}\" class=\"link \" rel=\"nofollow noopener\" target=\"_blank\">editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors&hellip;\n","protected":false},"author":2,"featured_media":433761,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[114,203398,109026,11628,85,77209,46,6943,13132,56414],"class_list":["post-433760","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-clov","tag-clover-health","tag-fair-value","tag-il","tag-intrinsic-value","tag-israel","tag-medicare-advantage","tag-share-price","tag-total-shareholder-return"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/433760","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=433760"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/433760\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/433761"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=433760"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=433760"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=433760"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}